Use our account feature to register for a free CLI account. Your new account will allow you to bookmark and organize articles and research for easy reference later - making it simple to keep track of the research that's important to you!
Register / Sign in
close-panel

Charlotte Lozier Institute

Phone: 202-223-8073
Fax: 571-312-0544

2776 S. Arlington Mill Dr.
#803
Arlington, VA 22206

Get Notifications

Sign up to receive email updates from Charlotte Lozier Institute.

Become A Defender of Life

Your donation helps us continue to provide world-class research in defense of life.

DONATE

Charlotte Lozier Institute

Phone: 202-223-8073
Fax: 571-312-0544

2776 S. Arlington Mill Dr.
#803
Arlington, VA 22206

Chemical AbortionLife & the Law Issues in Law & Medicine

United Kingdom Data Deficiencies Influencing U.S. FDA Decisions

Additional authors: Calum Miller, MD and Kevin Duffy, MPH

 

Abstract

The U.S. FDA has permanently removed the in-person prescribing requirements that previously safeguarded the use of mifepristone/misoprostol medical abortions, allowing prescribing through telemedicine or on-line ordering and distribution through the mail and pharmacies, without standard pre-abortion testing. This will increase the risk of complications due to failure to adequately determine the gestational age or rule out ectopic pregnancy by ultrasound or physical exam, failure to perform labs to document whether RhoGAM is indicated, and failure to obtain appropriate informed consent to prevent unwanted abortions, among other concerns. The FDA justified this action by referencing flawed studies with significantly undercounted complications. The details of these study deficiencies are examined in this paper.

Read Complete Article

Latest Posts

June 3, 2024 Abortion Reporting: Arkansas (2023) May 29, 2024 Abortion Reporting: West Virginia (2023) May 29, 2024 Abortion Reporting: Indiana (2023)

You Might Also Be Interested In

New Study Reveals FDA Relied on Cherrypicked Data to Approve Dangerous Mail-Order Abortion Drugs

New Study Reveals FDA Relied on Cherrypicked Data to Approve Dangerous Mail-Order Abortion Drugs

charlotte-lozier-institute Charlotte Lozier Institute
May 13, 2024
ClosePlease login

Fact Sheet: Three Problems with the FDA’s Abortion Drugs Complications Data

March 22, 2024
ClosePlease login

Filed: CLI Amicus Brief in SCOTUS Case FDA v. Alliance for Hippocratic Medicine

charlotte-lozier-institute Charlotte Lozier Institute
March 21, 2024
ClosePlease login

Become A Defender of Life

Your donation helps us continue to provide
world-class research in defense of life.

BECOME A PARTNER
cta-image